A meta-analysis of the efficacy and safety of unboosted atazanavir compared with ritonavir-boosted protease inhibitor maintenance therapy in HIV-infected adults with established virological suppression after induction

HIV Medicine

Volumn 15, Issue 5, 2014, Pages 301-310

  Baril, J ^a   Conway, B ^b   Giguere P ^c   Ferko, N ^d   Hollmann, S ^d   Angel, J B ^c  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^d Department of Data Analytics and Evidence Synthesis   (Canada)

Author keywords

Atazanavir; HIV; Meta analysis; Ritonavir; Unboosted

Indexed keywords

ATAZANAVIR; INDINAVIR PLUS RITONAVIR; LOPINAVIR PLUS RITONAVIR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; RITONAVIR; RITONAVIR PLUS SAQUINAVIR; TRIACYLGLYCEROL; VIRUS RNA;

ARTICLE; CD4 LYMPHOCYTE COUNT; CHOLESTEROL BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; MAINTENANCE THERAPY; META ANALYSIS; PRIORITY JOURNAL; THERAPY;

ATAZANAVIR; HIV; META-ANALYSIS; RITONAVIR; UNBOOSTED;

DRUG SUBSTITUTION; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HUMANS; MAINTENANCE CHEMOTHERAPY; OLIGOPEPTIDES; PROTEASE INHIBITORS; PYRIDINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RITONAVIR;

EID: 84897450953     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/hiv.12118     Document Type: Article

References (30)

1. Thompson MA, Aberg JA, Hoy JF etal. Antiretroviral treatment of adult HIV infection. 2012 recommendations on the international antiviral society - USA Panel. JAMA 2012; 308: 387-402.
2. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Available at: http://aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf (accessed 15 May 2013).
3. Ghosn J, Carosi G, Moreno S etal. Unboosted Atazanavir-based therapy maintains control of HIV type-1 replication as effectively as a ritonavir-boosted regimen. Antivir Ther 2010; 15: 993-1002.
4. Cooper CL, van Heeswijk RP, Gallicano K, Cameron DW. A review of low-dose ritonavir in protease inhibitor combination therapy. Clin Infect Dis 2003; 36: 1585-1592.
5. Iloeje UH, Yuan Y, L'italien G etal. Protease inhibitor exposure and increased risk of cardiovascular disease in HIV-1 infected patients. HIV Med 2005; 6: 37-44.
6. Friis-Moller N, Sabin CA, Weber R etal. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003; 349: 1993-2003.
7. DAD Study Group, Friis-Moller N, Reiss P etal. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007; 356: 1723-1735.
8. Calza L, Manfredi R, Farneti B, Chiodo F. Incidence of hyperlipidemia in a cohort of 212 HIV-infected patients receiving a protease inhibitor-based antiretroviral therapy. Int J Antimicrob Agents 2003; 22: 54-59.
9. Shafran SD, Mashinter LD, Roberts SE. The effect of low-dose ritonavir monotherapy on fasting serum lipid concentrations. HIV Med 2005; 6: 421-425.
10. Carey D, Amin J, Boyd M, Petoumenos K, Emery S. Lipid profiles in HIV-infected adults receiving Atazanavir and Atazanavir/ritonavir: systematic review and meta-analysis of randomized controlled trials. J Antimicrob Chemother 2010; 65: 1878-1888.
11. Monforte AD, Reiss P, Ryom L etal. Atazanavir is not associated with an increased risk of cardio- or cerebrovascular disease events. AIDS 2013; 27: 407-415.
12. TM (Atazanavir sulfate) Azapeptide Inhibitor of HIV-1 Protease. Quebec, Canada. Prepared December 3, 2003 (Revised May 11, 2012). Control Number: 154449.
13. TM (Atazanavir sulfate). New Jersey, USA. Approved 2003. Revised March 2012. 1246226B2. 687US11PBS05504.
14. Squires KE, Young B, Dejesus E etal. Similar efficacy and tolerability of Atazanavir compared with Atazanavir/ritonavir, each with abacavir/lamivudine after initial suppression with abacavir/lamivudine plus ritonavir-boosted Atazanavir in HIV-infected patients. AIDS 2010; 24: 2019-2027.
15. Focà E, Ripamonti D, Motta D, Torti C. Unboosted Atazanavir for treatment of HIV infection: rationale and recommendations for use. Drugs 2012; 72: 1161-1173.
16. Malan DR, Krantz E, David N etal. 96-week efficacy and safety of atazanavir, with and without ritonavir, in a HAART regimen in treatment-naive patients. J Int Assoc Physicians AIDS Care (Chic) 2010; 9: 34-42.
17. Higgins JPT, Green S, eds. Cochrane handbook for systematic reviews of interventions version 5.1.0. The Cochrane Collaboration. 2011. Available at: http://www.cochrane-handbook.org (accessed 20 August 2012).
18. Wohl D, Bhatti L, Small CB etal. Simplification to Abacavir/Lamivudine + Atazanavir From Tenofovir/Emtricitabine + Atazanavir/Ritonavir Maintains Viral Suppression and Improves Bone Biomarkers. Oral Abstract H-556c. 52nd ICAAC. San Francisco, CA. September 9-12, 2012.
19. Soriano V, García-Gasco P, Vispo E etal. Efficacy and safety of replacing lopinavir with Atazanavir in HIV-infected patients with undetectable plasma viraemia: final results of the SLOAT trial. J Antimicrob Chemother 2008; 61: 200-205.
20. Gatell J, Salmon-Ceron D, Lazzarin A etal. Efficacy and safety of Atazanavir-based highly activeantiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN study (AI424-097) 48-week results. Clin Infect Dis 2007; 44: 1484-1492.
21. D'arminio Monforte A, Reiss P, Ryom L etal. Atazanavir (ATV)-Containing Antiretroviral Treatment is not Associated with an Increased Risk of Cardio- or Cerebro-Vascular Events (CVE) in the D:A:D Study. [Poster No. 823]. CROI 2012.
22. Giuntini R, Martinelli C, Ricci E etal. Efficacy and safety of boosted and unboosted atazanavir-containing antiretroviral regimens in real life: results from a multicentre cohort study. HIV Med 2010; 11: 40-45.
23. Santos JR, Moltó J, Llibre JM etal. Unboosted atazanavir plus co-formulated lamivudine/abacavir as a ritonavir-sparing simplification strategy in routine clinical practice. HIV Clin Trials 2009; 10: 129-134.
24. Hocqueloux L, Le Moal G, De la Tribonnier X etal. Maintenance therapy with unboosted atazanavir is comparable to boosted strategy in experienced patients, even with tenofovir: a multicentre propensity-adjusted cohort. 6th IAS conference on HIV pathogenesis, treatment and prevention. Rome, July 2011 [Abstract no. CDB359].
25. Pavie J, Porcher R, Torti C etal. Efficacy and safety of a switch to unboosted atazanavir in combination with nucleoside analogues in HIV-1-infected patients with virological suppression under antiretroviral therapy. J Antimicrob Chemother 2011; 66: 2372-2378.
26. Wentzell J, Kravcik S, Giguere P. Efficacy of boosted and unboosted atazanavir-based therapy in patients without prior antiretroviral treatment failure [abstract P079]. Can J Infect Dis Med Microbiol 2012; 23 (Suppl A): 66A.
27. Cohen C, Nieto-Cisneros L, Zala C etal. Comparison of atazanavir with lopinavir/ritonavir in patients with prior protease inhibitor failure: a randomized multinational trial. Curr Med Res Opin 2005; 21: 1683-1692.
28. Atazanavir: new recommendations if combined with tenofovir (Viread) - and warning on Viagra, Cialis, and Levitra. AIDS Treat News 2004; 399: 5.
29. Fournier C, Higgins N, Thomas R etal. Negligible effect of tenofovir on atazanavir trough concentrations and genotypic inhibitory quotients in the presence and absence of ritonavir. Ther Drug Monit 2013; 35: 264-269.
30. Squires K, Young B, Dejesus E etal. Similar efficacy and tolerability of atazanavir (ATV) compared to ATV/ritonavir (RTV), each in combination with abacavir/lamivudine (ABC/3TC) after initial suppression with ABC/3TC + ATV/RTV in HIV-1 infected patients: Final (144 weeks) results of the op. 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention. Rome, July 2011 [Abstract no. MOPE215].